Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_assertion type Assertion NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_head.
- NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_assertion description "[The importance of achieving a very good partial response or better (?VGPR) after induction treatment of myeloma has traditionally only been discussed in the context of high-dose therapy with auto-SCT (HDT/auto-SCT).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_provenance.
- NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_assertion evidence source_evidence_literature NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_provenance.
- NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_assertion SIO_000772 20154737 NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_provenance.
- NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_assertion wasDerivedFrom befree-20140225 NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_provenance.
- NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_assertion wasGeneratedBy ECO_0000203 NP542375.RA-x50TtwL3Y4W30PmqeLfQX0j9hrW3dagUL7BqjAoRLg130_provenance.